Presentation from Dr. Alan Lewis

Research Update Alan J. Lewis, PhD President & CEO April 6, 2009

JDRF: Constituents and Roadmap ,[object Object],[object Object],[object Object],[object Object],T1D “Cure” Product A Academic Community Biotech Companies Pharma and Device Companies Product B Product C

We are Building a Bridge to the Cure!

Type 1 Diabetes Landscape ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Current Treatment For Type 1 Diabetes Relies On Insulin Replacement ,[object Object],[object Object],[object Object],1st Line 50% of patients 1 year Basal-Bolus 2nd Line 3rd Line Addition of insulin pumps and use of Symlin as co-therapy 4th Line Last Line 10% of patients N/A ,[object Object],[object Object],[object Object],[object Object],40% of patients receiving pumps Source: L.E.K. Interviews and Analysis Increasing Severity

Pancreas Derived Endocrine Cells

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Therapeutic Integration Requires Close Collaboration across JDRF Therapeutic Areas

JDRF’s Research: Type 1 Diabetes Person/Patient Centric Orientation Established Diabetes Recent Onset Diabetes Pre-diabetes Prevent Beta Cell Destruction Preserve Residual Beta Cells Restore Beta Cells, Beta Cell Function

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Therapeutic Area Programs: FY09 Key Developments

We Did It! ,[object Object],[object Object],[object Object]

Replacement and Regeneration ,[object Object],ß -cell Progenitors T1D Patient hESC Insulin Producing ß-cell iPS 1 2 3 4

Functional Islets from hESCs Toward a renewable source of pancreatic  -cells Kroon et al. v.26; April 2008

Adult Human Islet vs. hESC “Islet” Cell Grafts Human Islet Graft Implant days : 360 hESC-Islet Graft Implant days : 377 Glucagon Somatostatin Insulin

Delivery of Human Islets Without Immunosuppression Immune Cells Complement 0 2 Nutrients GLUCOSE INSULIN C-Peptide Human Islet PEG 25-50 

Future of… Insulin Producing Cell Transplantation: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],Therapeutic Area Programs: FY09 Key Developments

JDRF’s Artificial Pancreas Project ,[object Object],[object Object]

JDRF Artificial Pancreas Outreach

JDRF’s Role in Catalyzing Reimbursement and Adoption of CGM ,[object Object],[object Object],[object Object]

JDRF Continuous Glucose Monitor Trial

[object Object],[object Object],[object Object],[object Object],[object Object],JDRF CGM Trial: Key Findings

JDRF – Pharma Strategy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],JDRF as the Patient Advocate for a Cure

[object Object],[object Object],[object Object],[object Object],Proposed Short-term Deliverables Related to Potential Immediate T1D Clinical Impact

Progress Towards the Cure…One Step at a Time ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

$ Millions Total Research Commitments New Research Commitments *projected * * * * * * $ Millions *projected Historical Context for Current FY09- FY11 Projections

[object Object],[object Object],[object Object],[object Object]

Presentation from Dr. Alan Lewis

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Semelhante a Presentation from Dr. Alan Lewis

Semelhante a Presentation from Dr. Alan Lewis (20)

Mais de JDRF New England Chapter

Mais de JDRF New England Chapter (13)

Último

Último (20)

Presentation from Dr. Alan Lewis